genetic screening
Human beings are big data. We aren’t just 175 pounds of meat and bone. We aren’t just piles of hydrogen and carbon and oxygen. What makes us all different is how it’s all organized and that is information.
We can no longer treat people based on simple numbers like weight, pulse, blood pressure, and temperature. What makes us different is much more complicated than that.
source: by Timothy Hay When the Food and Drug Administration told personal-genetics company 23andMe Inc. in November to stop sending consumers detailed information about their DNA, some industry watchers said the move could be a devastating blow to an emerging area of medicine that holds promise for better health outcomes. But it was more of […]
Read More
Our portfolio company Assurex Health just announced the creation of a partnership with Canada’s Center for Addiction and Mental Health (CAMH), one of the world’s leading research centers in the area of addiction and mental health and Canada’s largest mental health teaching hospital. CAMH will offer to Canadian citizens the firm’s pharmacogenomic test, GeneSight, which […]
Read More
Our portfolio company Assurex Health, announced recently the publication of a groundbreaking analysis of pharmacogenomic data in the International Review of Psychiatry. The publication strongly validates the premise that the clinical use of genomic testing to help predict patient response to psychiatric medications significantly improves treatment outcomes. This is a key milestone in the continuing […]
Read More
Thursday June 20, 2013, Atul Butte, MD, PhD, a Stanford University Professor and entrepreneur is being honored at a formal ceremony in the White House Rose Garden in Washington DC. The Obama Administration is honoring Dr. Butte and several other genomics and molecular biology researchers who have focused on making large and complex sets of […]
Read MoreCongratulations to Claremont Creek portfolio company Natera on closing a $54.6 million financing round. Given Claremont Creek Venture’s involvement since the company’s earliest round of financing, we know Natera is on its way to dominating the market for noninvasive, prenatal genetic testing. The financing is just the latest recent milestone for the company. In February […]
Read MoreMeet our team
Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.
NAT GOLDHABER
Nat Goldhaber is a co-founder of Claremont Creek Ventures.
BRAD WEBB
Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.
RANDY HAWKS
Randy Hawks is a co-founder of Claremont Creek Ventures.